Test ID: FPMET
Prometheus Thiopurine Metabolites
Secondary ID 
A test code used for billing and in test definitions created prior to November 2011
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Method Name A short description of the method used to perform the test
High Performance Liquid Chromatography (HPLC)
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Aliases Lists additional common names for a test, as an aid in searching
6 Thioguanine (6TG) FORWARD
Imuran Metabolite
Pro Predict 6 MP FORWARD
PRO-Predict 6 MP FORWARD
PRO-PredictRx 6 MP FORWARD
Prometheus 6 MP FORWARD
Prometheus Metabolites (thiopurine therapy) FORWARD
ProPredict 6 MP FORWARD
Specimen Type Describes the specimen type needed for testing
Specimen Required Defines the optimal specimen. This field describes the type of specimen required to perform the test and the preferred volume to complete testing. The volume allows automated processing, fastest throughput and, when indicated, repeat or reflex testing.
Draw 5 mL EDTA whole blood. Submit EDTA whole blood promptly
at refrigerated temperature.
Specimen Minimum Volume Defines the amount of specimen required to perform an assay once, including instrument and container dead space. Submitting the minimum specimen volume makes it impossible to repeat the test or perform confirmatory or perform reflex testing. In some situations, a minimum specimen volume may result in a QNS (quantity not sufficient) result, requiring a second specimen to be collected.
Reject Due To Identifies specimen types and conditions that may cause the specimen to be rejected
| Specimens other than | Whole blood |
| Anticoagulants other than | EDTA |
| Hemolysis | NA |
| Thawing | NA |
| Lipemia | NA |
| Icteric | NA |
Specimen Stability Information Provides a description of the temperatures required to transport a specimen to the laboratory. Alternate acceptable temperature(s) are also included.
| Specimen Type | Temperature | Time |
|---|---|---|
| Whole Blood EDTA | Refrigerated (preferred) | 8 days |
| Ambient | 24 hours |
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Units of Measure: pmol/8 x 10(8) RBC
Metabolite Reference Range
6-TGN 230-400
6-MMPN <5700
Proprietary and patented technology by Prometheus Laboratories,
Inc. The therapeutic range and toxic thresholds were established
in an IBD patient population receiving azathioprine or
6-mercaptopurine. Metabolite testing should not replace
laboratory monitoring for toxicity.
Graph available upon request.
Test Performed By: Prometheus Laboratories, Inc.
Therapeutics and Diagnostics
9410 Carroll Park Drive
San Diego, CA 92121-4203
Clinical Reference Provides recommendations for further in-depth reading of a clinical nature
Dubinsky M, et al. Pharmacogenomics and metabolite
measurement for 6-mercaptopurine therapy in patients with
inflammatory bowel disease. Gastroenterology. 2000;118:705-713.
Seidman EG. Recent Advances in the diagnosis and treatment
of pediatric inflammatory bowel disease. Gastroenterol Rep.2000;
1:248-252.
Cuffari C, et al. Utilisation of erythrocyte 6-thioguanine metabolite
levels to optimize azathioprine therapy in patients with inflammatory
bowel disease. Gut. 2001;48:642-646.
Seidman, EG. Clinical use and practical application of TPMT Enzyme
and 6-mercaptopurine metabolite monitoring in IBD. Rev
Gastroenterol Disord. 2003;3(suppl 1):S30-S38.
Rumbo C, et al. Azathioprine metabolite measurements in the
treatment of autoimmune hepatitis in pediatric patients: A preliminary
report. J Ped Gastro Nutr. 2002;35:391-398.
Lennard L, et al. The clinical pharmacology of 6-mercaptopurine.
Eur J Clin Pharmacol. 1992;43(4):329-339.
Lennard L. Clinical implication of thiopurine methyltransferase-Optimization
of drug dosage and potential drug interactions. Ther Drug Monit 1998;
20(5):527-531.
Louis E, Belaiche J. Optimizing treatment with thioguanine derivative
in inflammatory bowel disease. Best Pract Res Clin Gastroenterol
2003;17(1):37-46.
Analytic Time Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.
Maximum Laboratory Time Defines the maximum time from specimen receipt at Mayo Medical Laboratories until the release of the test result
Specimen Retention Time Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location The location of the laboratory that performs the test
CPT Code Information Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Medical Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
82491/x2
LOINC® Code Information Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the result codes returned for this test or profile.
| Result ID | Reporting Name | LOINC Code |
|---|---|---|
| Z1501 | 6-TGN Metabolite Result | In Process |
| Z1502 | 6-TGN Metabolite Result Assessment | In Process |
| Z1503 | 6-MMPN Metabolite Result | In Process |
| Z1504 | 6-MMPN Metabolite Result Assessment | In Process |
External
link
PDF
document
Excel
document
Word
document